Trial Profile
MIR-CABG: A Randomized, Double-blind, Placebo-controlled, Single-Center Study to Evaluate the Impact of Mupirocin on Infection Rate Post Coronary Artery Bypass Grafting
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Oct 2013
Price :
$35
*
At a glance
- Drugs Mupirocin (Primary)
- Indications Staphylococcal infections; Surgical wound infections
- Focus Therapeutic Use
- Acronyms MIR-CABG
- 15 Oct 2013 New trial record